SPRINT Sprint Bioscience AB (publ)

0.3629USD3.680 SEK · STO-3.16%Mkt Cap: 38.29M USDP/E: 5.26

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by…

Key Statistics

Company
Market Cap38.29M USD
Enterprise Value30.65M USD
Revenue (TTM)13.23M USD
Gross Profit15.19M USD
Net Income (TTM)9.05M USD
Revenue/Share0.13 USD
Last Price0.3629 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees33
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0006343745
Valuation
P/E (Trailing)5.26
P/E (Forward)2.83
PEG—
EV/EBITDA4.22
EV/Revenue2.32
P/S2.90
P/B5.12
EPS (TTM)0.07 USD
EPS (Forward)0.13 USD
52W Range
0.057077% of range0.4526
52W High0.4526 USD
52W Low0.0570 USD
Profitability
Gross Margin92.18%
Oper. Margin54.11%
EBITDA Margin54.96%
Profit Margin54.88%
ROE76.97%
ROA67.13%
ROIC—
ROCE81.85%
Growth
Revenue Growth-99.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF8.24M USD
CapEx (TTM)9.27K USD
FCF Margin31.34%
FCF Yield10.83%
Net Debt-7.64M USD
Net Debt/EBITDA-1.05
Net Debt/FCF-1.84
Balance Sheet
Debt/Equity—
Current Ratio6.49
Quick Ratio6.49
Book Value/Sh0.07 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.4930 USD
Upside (mean)+35.9%
Target Range0.4930 USD – 0.4930 USD
# Analysts1
Ownership
Shares Out.105.52M
Float93.41M
Insiders27.84%
Institutions39.33%
Technical
SMA 500.3380 (+7.4%)
SMA 2000.3194 (+13.6%)
Beta-0.63
S&P 52W Chg8.68%
Avg Vol (30d)247.44K
Avg Vol (10d)372.97K
Technical Indicators
RSI (14)49.6
MACD0.1044
MACD Signal0.1168
MACD Hist.-0.0124
BB Upper0.4123 USD
BB Middle0.3656 USD
BB Lower0.3190 USD
BB Width25.52%
ATR (14)0.0230 USD
Vol Ratio (20d)0.72x

About Sprint Bioscience (STO: SPRINT)

›

Sprint Bioscience (STO: SPRINT) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.

The shares were at 3.680 SEK on 20 November 2026, up 467.9% over 52 weeks. Its 52-week range is 0.5780 SEK to 4.590 SEK: the price is 19.8% below the high and 536.7% above the low.

At a market capitalisation of 388.30M SEK, it trades at 5.3 times trailing earnings and 2.8 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a discount of 84% for SPRINT.

Sprint Bioscience reports return on equity of 77.0%, an operating margin of 54.1% and revenue down 99.7% year over year.

It holds more cash than debt, a net cash position of 77.52M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 5.000 SEK is 35.9% above the current price.